Early renal failure detection by cystatin C in Type 2 diabetes mellitus: varying patterns of renal analyte expression

References

• Amos A F, McCarty D J, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabetic Med 1997; 14(Suppl 5)S7–85
   PubMed Web of Science ®Google Scholar
• Xue J L, Ma J Z, Louis T A, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753–8
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. NHMD. National Hospital Morbidity Database. Canberra: Australian Institute of Health and Welfare, 2004. 2004, http://www.aihw.gov.au/hospitals/nhm_database_nhmds.cfm (accessed February 2007)
   Google Scholar
• Lewis E J, Hunsicker L G, Clarke W R, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60
   PubMed Web of Science ®Google Scholar
• Watanabe S, Okura T, Kurata M, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006; 28: 451–61
   PubMed Web of Science ®Google Scholar
• Mussap M, Dalla Vestra M, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453–61
   PubMed Web of Science ®Google Scholar
• Tan G D, Lewis A V, James T J, et al. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 2002; 25: 2004–9
   PubMed Web of Science ®Google Scholar
• Shimizu A, Horikoshi S, Rinnno H, et al. Serum cystatin C may predict the early prognostic stages patients with type 2 diabetic nephropathy. J Clin Lab Anal 2003; 17: 164–7
   PubMed Web of Science ®Google Scholar
• Kramer H J, Nguyen Q D, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273–7
   PubMed Web of Science ®Google Scholar
• Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Levey A S, Bosch J P, Lewis J B, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461–70
   PubMed Web of Science ®Google Scholar
• Grubb A, Bjork J, Lindstrom V, et al. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005; 65: 153–62
   PubMed Web of Science ®Google Scholar
• Poggio E D, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft Gault equations in the estimation of GFR in health and inchronic kidney Disease. J Am Soc Nephrol 2005; 16: 459–66
   PubMed Web of Science ®Google Scholar
• National kidney Foundation. KDOQI Guidelines, Kidney Disease Outcomes Quality Initiative. National Kidney Foundation, New York 1997, http://www.kidney.org/professionals/KDOQI/guidelines/ (accessed February 2007)
   Google Scholar
• Abrahamson M, Barret A, Grubb A. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem 1986; 261: 11282–9
   PubMed Web of Science ®Google Scholar
• Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38(Suppl 1)S20–7
   PubMed Web of Science ®Google Scholar
• Schuck O, Teplan V, Stollova M, et al. Estimation of glomerular filtration rate in obese patients with chronic renal impairment based on serum cystatin C levels. Clin Nephrol 2004; 62: 92–96
   PubMed Web of Science ®Google Scholar
• Harmoinen A, Lehtimaki T, Korpela M, et al. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft Gault and Levey (MDRD) formulas. Clin Chem 2003; 49: 1223–5
   PubMed Web of Science ®Google Scholar
• Hoek F J, Kemperman F A, Krediet R T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024–31
   PubMed Web of Science ®Google Scholar
• Christensson A G, Grubb A O, Nilsson J A, et al. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med 2004; 256: 510–8
   PubMed Web of Science ®Google Scholar
• Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115–22
   PubMed Web of Science ®Google Scholar
• Finney H, Newman D J, Price C P. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000; 37: 49–59
   PubMed Web of Science ®Google Scholar
• Kyhse-Andersen J, Schmidt C, Nordin G. ‘Serum cystatin C, determined by a rapid, automated particle enhanced turbidimetric method, is a better marker than serum creatinine for GFR. Clin Chem 1994; 40: 921–6
   Web of Science ®Google Scholar
• Norlund L, Fex G, Lanke J, et al. ‘Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum beta 2 microglobulin/cystatin C-ratio’. Scand J Clin Lab Invest 1997; 57: 463–70
   PubMed Web of Science ®Google Scholar
• Page M K, Bukki J, Luppa P, et al. Clinical value of cystatin C determination. Clin Chim Acta 2000; 297: 67–72
   PubMed Web of Science ®Google Scholar
• Pergande M, Jung K. Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies. Clin Chem 1993; 39: 1885–90
   PubMed Web of Science ®Google Scholar
• Newman D J, Thakkar H, Edwards R G, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312–8
   PubMed Web of Science ®Google Scholar
• Dharnidharka V R, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221–6
   PubMed Web of Science ®Google Scholar
• Laterza O F, Price C P, Scott M G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem 2002; 48: 699–707
   PubMed Web of Science ®Google Scholar
• Schuck O, Teplan V, Jabor A, et al. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels. Nephron Clin Pract 2003; 93: 146–51
   Google Scholar
• Dade Behring N, Latex Cystatin C, Kit Method B N, II. Nephelometer. Dade Behring, EschbornGermany 2005
   Google Scholar
• Finney H, Newman D J, Price C P. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000; 37: 49–59
   PubMed Web of Science ®Google Scholar
• Wasen E, Isoaho R, Mattila K, et al. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med 2004; 256: 70–78
   PubMed Web of Science ®Google Scholar
• Olivieri O, Bassi A, Pizzolo F, et al. Cystatin C versus creatinine in renovascular disease. Clin Chem 2002; 48: 2256–9
   PubMed Web of Science ®Google Scholar
• Uhlmann E J, Hock K G, Issitt C, et al. Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine. Clin Chem 2001; 47: 2031–3
   PubMed Web of Science ®Google Scholar
• Mussap M, Vestra M, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453–61
   PubMed Web of Science ®Google Scholar
• Newman D J, Thakkar H, Edwards R G, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312–8
   PubMed Web of Science ®Google Scholar
• Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for non invasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29–34
   PubMed Web of Science ®Google Scholar
• Shimamura T, Morrison A. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 1975; 79: 95–106
   PubMed Web of Science ®Google Scholar
• Placha G, Poznik G D, Dunn J, et al. A genome-wide linkage scan for genes controlling variation in renal function estimated by serum cystatin C levels in extended families with type 2 diabetes. Diabetes 2006; 55: 3358–65
   PubMed Web of Science ®Google Scholar
• Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S–92
   PubMed Web of Science ®Google Scholar
• Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216–22
   PubMed Web of Science ®Google Scholar
• Working Group on Hypertension. Statement on hypertension in diabetes. Diabetes Care 1987; 10: 764–76
   PubMed Web of Science ®Google Scholar
• Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus; a 7-year follow-up study. Arch Intern Med 1996; 156: 286–9
   PubMed Web of Science ®Google Scholar
• Lovell H G. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev 2001; 1, CD002183
   Google Scholar
• Lewis E J, Hunsicker L G, Bain R P, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–62
   PubMed Web of Science ®Google Scholar
• Stevens L A, Coresh J, Schmid C H, et al. Estimating GFR using serum cystatin c alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395–406
   PubMed Web of Science ®Google Scholar
• Koenig W, Twardella D, Brenner H, et al. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005; 51: 321–7
   PubMed Web of Science ®Google Scholar
• O'Hare A M, Newman A B, Katz R, et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Int Med 2005; 165: 2666–70
   PubMedGoogle Scholar
• Ni L, Lu J, Hou L B, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007; 38: 3287–8
   PubMed Web of Science ®Google Scholar